Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis

By LabMedica International staff writers
Posted on 11 Sep 2025

Ovarian cancer is considered one of the deadliest cancers, in part because it rarely shows clear symptoms in its early stages, and diagnosis is often complex. More...

Current approaches make it difficult to accurately triage women with ovarian cancer compared to benign conditions, and often require painful, invasive procedures such as tissue biopsies. Researchers have now developed a new nanoparticle-based approach that can highlight ovarian cancer markers more accurately than current diagnostic tools.

A project led by The University of Queensland (Brisbane, Australia) and collaborators has led to the development of a technology that uses sponge-like mesoporous gold nanoparticles to improve cancer diagnostics through their unique biosensing properties. These structures act as light amplifiers, revealing even the faintest traces of cancer markers in patient samples such as urine, saliva, or blood.

Researchers boosted the sensitivity of gold-enhanced light sensors using Surface-Enhanced Raman Scattering (SERS). Compared with commercially available nanoparticles, mesoporous gold increased sensitivity significantly, enabling tiny "hotspots" of light to amplify biomarker signals. Embedded into a diagnostic process with a small tube and handheld Raman spectrophotometer, the method has already outperformed current blood tests, achieving 82% sensitivity in confirming ovarian cancer and 98% specificity in ruling it out. The research was published in the nanoscience and nanotechnology journal Small.

The portability, affordability, and simplicity of this sensor technology make it especially promising for women in remote or under-resourced regions. By transforming disease monitoring, mesoporous nanotechnologies could reduce unnecessary procedures and help pave the way for more personalized treatment strategies. With further development, devices like this could move closer to everyday clinical use, improving survival rates through earlier and more accurate detection.

“This project demonstrates how mesoporous nanotechnologies can help us transform disease monitoring and pave the way for personalized treatment strategies,” said Javeria Bashir, nanomaterials researcher at The University of Queensland and lead developer of the technology. “Devices like this are moving closer and closer to everyday use.”

Related Links:
The University of Queensland


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Automated Clinical Chemistry Analyzer
Envoy 500+
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.